Indication
For use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

Medicine details

Medicine name:
pertuzumab (Perjeta)
SMC ID:
SMC2120
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Advice due date:
14 January 2019
SMC meeting date:
04 December 2018
Patient group submission deadline:
05 November 2018